Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment.

Fu C, Jiang A. · 2018

Read Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment. by Fu C, Jiang A. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6306491.txt.

Introduction

Fu and Jiang review how dendritic cells shape CD8 T cell immunity in tumors. The review appeared in Frontiers in Immunology. Dendritic cells present tumor material to T cells. This cross-priming can spark attacks on the cancer. The tumor setting often twists that process. It can turn priming toward tolerance instead.

The authors focus on one dendritic cell subset. These CD103+ type 1 cells drive cross-priming best. They show how tumors suppress these cells. They also weigh ways to restore their function. Future directions include memory T cell responses. Better dendritic cell support could strengthen cancer immunotherapy.

Catalog record

CREATORFu C, Jiang A.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE63 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6306491

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment By Chunmei Fu, Aimin Jiang Published in: Frontiers in Immunology DOI: 10.3389/fimmu.2018.03059 ABSTRACT Abstract Dendritic cells (DCs) play a central role in the regulation of the balance between CD8 T cell immunity vs. tolerance to tumor antigens. Cross-priming, a process which DCs activate CD8 T cells by cross-presenting exogenous antigens, plays a critical role in generating anti-tumor CD8 T cell immunity. However, there are compelling evidences now that the tumor microenvironment (TME)-mediated suppression and modulation of tumor-infiltrated DCs (TIDCs) impair their function in initiating potent anti-tumor immunity and even promote tumor progression. Thus, DC-mediated cross-presentation of tumor antigens in tumor-bearing hosts often induces T cell tolerance instead of immunity. As tumor-induced immunosuppression remains one of the major hurdles for cancer immunotherapy, understanding how DCs regulate anti-tumor CD8 T cell immunity in particular within TME has been under intensive investigation. Recent reports on the Batf3-dependent type 1 conventional DCs (cDC1s) in anti-tumor immunity have greatly advanced our understanding on the interplay of DCs and CD8 T cells in the TME, highlighted by the critical role of CD103+ cDC1s in the cross-priming of tumor antigen-specific CD8 T cells. In this review, we will discuss recent advances in anti-tumor CD8 T cell cross-priming by CD103+ cDC1s in TME, and share perspective on future directions including therapeutic applications and memory CD8 T cell responses. Keywords: CD103+ cDC1s, CD8 T cell immunity, anti-tumor immunity, cross-priming, tumor microenvironment, cancer immunotherapy INTRODUCTION Cancer is characterized by the accumulation of genetic mutations and the loss of normal cellular regulatory functions (1). The identification of tumor-associated antigens (TAAs) that separated cancerous cells from non-transformed healthy cells, and the observation of tumor antigen-specific CD8 T cells in cancer patients have greatly advanced our understanding on tumor immunology and formed the basis for antigen-specific immunotherapy (2). The first human tumor antigen recognized by CD8 cytotoxic T lymphocytes (CTL) was identified in melanoma and was designated melanoma-associated antigen (MAGE)-1 (3). The isolation of tumor-specific CTL from peripheral blood or tumor tissue of patients from various cancer patients provided evidence for existence of CD8 T cell-mediated anti-tumor immunity (4–7). The detection of TAA-specific CD8 T cells in spontaneously regressing tumors further supported the importance of tumor-specific CD8 T cell responses (5). It is well accepted now that CD8 T cells play a central role in mediating anti-tumor immunity, and their effector CTLs eliminate tumor cells by recognizing tumor-associated antigens presented on major histocompatibility complex class I (MHCI) by their expressed T cell receptor (TCR). Indeed, studies have shown that infiltration of T cells, especially CD8 T cells into tumor microenvironment, correlates with better prognosis in multiple malignancies such as breast, lung, melanoma, colorectal, and brain cancer (8, 9). However, even when tumor-specific CD8 T cell responses were observed, they rarely provided protective immunity as tumors often evade immune surveillance by dampening T cell effector and memory functions (10, 11). Promising cancer immunotherapies that aim to boost CD8 T cell-mediated anti-tumor immunity include DC cancer vaccines, adaptive cell transfer (ACT) of tumor-reactive T cells, either native (CTL clones or Tumor infiltrated lymphocytes–TIL) or engineered to express tumor antigen-specific TCR or chimeric antigen receptors (CAR), and immune checkpoint blockade (ICB) such as anti-PD-1, anti-PD-L1, and anti-CTLA-4 (2). Among them, immunotherapies with ICB and CAR T cells have achieved unprecedented clinical efficacy leading to a number of drugs being approved by the FDA. However, a majority of patients still fail to respond to these checkpoint or CAR T cell therapies, and many patients that do respond often experience relapse (12). While direct presentation of tumor antigens onto their MHCI by tumor cells play an important role in effector function of CD8 T cells, cross-presentation by professional antigen presenting cells in particular DCs are required for prime naive CD8 T cells and sustaining the cytotoxic immune responses (13). Thus, increasing efforts has been made to repair and enhance insufficient T cell priming by DCs to further improve the efficacy of immunotherapies with ICB and CAR T cells due to DCs' critical role in priming and directing CD8 T cells to target tumor cells (12, 14). Indeed, the ability of DCs to cross-present exogenous tumor-associated antigens onto MHCI molecule to prime CD8 T cells is the foundation of the “Cancer-Immunity cycle” proposed by Chen and Mellman (11). Thus, better understanding the interaction of CD8 T cells and DCs would be critical to improve the efficacy of current cancer immunotherapies. DENDRITIC CELLS AND TUMOR MICROENVIRONMENT Ralph Steinman was awarded the 2011 Nobel Prize for Medicine or Physiology for his pioneering work on DCs (15). As the sentinel of the immune system, DCs play a central role in linking innate and adaptive immune responses (16). Known as the most potent professional antigen presenting cells (APCs), DCs initiate all adaptive immune responses by uptaking, processing and presenting antigens including tumor antigens to activate naive antigen-specific CD4 and CD8 T cells (17). Since their identification in 1973 (18), DC development and the regulation of their function have been under intensive study. DCs originate in bone marrow from macrophage/DC progenitors (MDP) that give rise to common DC progenitors (CDP), which then differentiate into two major DC subsets: classical/conventional DCs (cDCs) and plasmacytoid DCs (pDCs) (19–26). Murine cDCs consist of two subtypes currently described as cDC1s (XCR1hiCD24hiCD26hiCD11chiMHCIIhi CD11bloCD172aloF4/80loCD64loLinlo,type 1 cDCs)andcDC2s(CD11bhiCD172ahiCD26hiCD11chiMHCIIhiXCR1loF4/80loCD64loLinlo, type 2 cDCs), and their human counterparts are CD141+ DCs (also known as BDCA3+) and CD1c+ DCs (also known as BDCA1+), respectively (27, 28). These two subtypes of cDCs differ in their transcriptional factor dependency, function and phenotypes (23, 24). cDC1 cells include lymphoid tissue CD8α+ cDC1s and migratory CD103+ cDC1s (29). cDC1 cells rely on interferon regulatory factor 8 (IRF8) and basic leucine zipper transcriptional factor ATF-like 3 (Batf3) for their development, and are specialized in presenting internalized exogenous antigens onto MHCI to prime CD8 T cells by cross-presentation (30). cDC2s depend on interferon regulatory factor 4 (IRF4) for their development and comprise a heterogeneous population that are very efficient in presenting internalized antigens on MHCII to activate CD4 T cells (31–34). pDCs are a multifunctional population best known for their specialized ability in producing and secreting large amount of type I interferons (IFNs) (35–37). pDCs also express high level of IRF8 similar to cDC1s, but require the E2-2 transcription factor for their development (38). E2-2, encoded by TCF4, is a member of the E family of basic helix–loop–helix transcription factors (39). In both mice and humans, E2-2 is required for the differentiation of pDCs from CDPs (38). Induced deletion of E2-2 in mature pDCs results in the acquisition of cDC-like properties, such as dendritic morphology, MHCII and CD8α expression, and the ability to induce proliferation of allogeneic CD4 T cells (40). Deletion of E2-2 in pDCs also induces the expression of ID2, which is required for cDC1 development. Murine pDCs express Siglec-H, B220, Ly6c, PDCA1 (CD317) and intermediate level of CD11c, and human pDCs express HLA-DR, CD123, BDCA2 (CD303), and BDCA4 (CD304) but not CD11c (36, 41). Initially reported as IFN-producing cells (IPCs), pDCs have been extensively studied for their function in sensing viral RNA and DNA by toll-like receptor (TLR)-7 and−9 (42, 43). In addition to their function in producing IFNs,

Read the complete text